The new health care law will create a policy limbo that is likely to persist for decades, increasing uncertainty, ultimately discouraging investment and scientific risk-taking.

Two recent experimental drugs demonstrate that new scientific principles are faster becoming superior medicines, but bad government policies threaten to reverse this trend.

Politicians wage broad wars on medicine to claim thin strips of ideological terrain. This would be good political theater if there weren't so many human victims.

Politicians wage broad wars on medicine to claim thin strips of ideological terrain. This would be good political theater if there weren't so many human victims.

European-style health care reforms could weaken the war on cancer.

Styrene's recent listing as "reasonably anticipated to be a human carcinogen" means something very different from how it is being framed by advocacy groups and the media—and this knowledge gap threatens to wreck legislative havoc across the country.

If the Food and Drug Administration's policy stands, cancer patients will have to wait many more years to get access to new drugs, and they will have fewer options in the process.

Politicians wage broad wars on medicine to claim thin strips of ideological terrain. This would be good political theater if there weren't so many human victims.